Chelsea Therapeutics (CHTP) – StreetInsider.com Reports
-
Wedbush Downgrades Chelsea Therapeutics (CHTP) to Neutral
-
Chelsea Therapeutics (CHTP) Reports Publication of Statistically Significant NORTHERA Phase 3 Data
-
Chelsea Therapeutics (CHTP) Presents Significant Date from Two Pivotal NORTHERA Studies
-
Chelsea Therapeutics (CHTP) Reports Expiration of HSR Act in Lundbeck Deal
-
Needham & Company Downgrades Chelsea Therapeutics (CHTP) to Hold on Pending Takeover
-
JMP Securities Downgrades Chelsea Therapeutics (CHTP) to Market Perform
-
Market Wrap: Initial Claims Drop; Strong McDonald's Sales in April; Fannie Still Profitable
-
Unusual 11 Mid-Day Movers 05/08: (TWGP) (CHTP) (WAC) Higher; (ISBC) (POWR) (RMGN) Lower
-
Lundbeck to Acquire Chelsea Therapeutics (CHTP) in $658M Deal
-
Lundbeck to Acquire Chelsea Therapeutics (CHTP) for $7.94/Share
-
Chelsea Therapeutics (CHTP) Partnership or Acquisition on Horizon - Wedbush
-
Chelsea Therapeutics International Ltd. (CHTP) Reports In-Line Q4 EPS
-
Notable 52-Week Highs and Lows of the Day 02/19: (CHTP) (NBR) (GRMN) High; (PBPB) (WTW) Low
-
Unusual 11 Mid-Day Movers 02/19: (ZLC) (CHTP) (OCLS) Higher; (GNK) (SM) (PRAN) Lower
-
Pre-Open Stock Movers 2/19: (ZLC) (CHTP) (GRMN) Higher; (SM) (GNK) (LZB) Lower (more...)
-
Chelsea Therapeutics (CHTP) Target Lifted to $10 at Needham & Company
-
Wedbush Comments on Chelsea Therapeutics (CHTP) and FDA Approval of NORTHERA,
-
Chelsea Therapeutics (CHTP) Price Target Raised to $8 at Deutsche Bank
-
After Hours Stock Movers 2/18: (CHTP) (UCTT) (COLM) Higher; (LZB) (MFRM) (PNRA) Lower (more...)
-
Market Wrap: King's New Game: IPO Crush; Major Healthcare Merger; Herbalife's Outlook Improves
-
Chelsea Therapeutics (CHTP) Confirms FDA Approval of NORTHERA
-
Chelsea Therapeutics (CHTP) to resume trading at 5:25PM
-
Chelsea Therapeutics (CHTP) NORTHERA approved by FDA
-
Chelsea Therapeutics (CHTP) trading halted with news pending
-
Chelsea Therapeutics (CHTP) Active Ahead of FDA's Delayed Decision on NORTHERA NDA
-
Pre-Open Stock Movers 2/18: (FRX) (VDSI) (ACT) Higher; (LIVE) (WM) (KO) Lower (more...)
-
Deutsche Bank Comments on Chelsea Therapeutics' (CHTP) Northera
-
Chelsea Therapeutics (CHTP) Active Again; Still No News
-
Chelsea Therapeutics (CHTP): No Decision Made by FDA on Northera NDA
-
Chelsea Therapeutics (CHTP) Halted Again on Circuit Breaker
-
UPDATE: Chelsea Therapeutics (CHTP) Whipsawed
-
Pre-Open Stock Movers 2/14: (LCAV) (LOGM) (CLF) Higher; (WTW) (GNC) (MW) Lower (more...)
-
Chelsea Therapeutics (CHTP) Up Early; NORTHERA PDUFA is Today
-
Chelsea Therapeutics (CHTP) Names Joseph Oliveto as CEO
-
Unusual 11 Mid-Day Movers 01/15: (CHTP) (DTLK) (LTRX) Higher; (QIWI) (NUS) (ORMP) Lower
-
Pre-Open Stock Movers 1/15: (CHTP) (DTLK) (TSLA) Higher; (XONE) (ELON) (NUS) Lower (more...)
-
Chelsea Therapeutics (CHTP) Has 20-100% Net Upside, Wedbush Said
-
Deutsche Bank Sees Chelsea Therapeutics (CHTP) Risk Skewed to the Downside ahead of Northera Approval
-
Chelsea Therapeutics (CHTP) Target Lifted to $8 at Needham & Company on FDA AdCom Support
-
After Hours Stock Movers 1/14: (CHTP) (DTLK) (GM) Higher; (XONE) (ATU) (HTWR) Lower (more...)
-
FDA CRDAC Committee Recommends Approval of Chelsea Therapeutics' (CHTP) NORTHERA
-
Unusual 11 Mid-Day Movers 01/10: (ICPT) (CNAT) (ECYT) Higher; (CHTP) (MNGA) (CERE) Lower
-
Streetinsider.com's Hot Lunchtime Reads 01/10: (AA) (TSLA) (CHTP) (TMO) (GM)
-
Chelsea Therapeutics (CHTP) Remains Outperform at Wedbush Despite Negative FDA Briefing Docs
-
Unusual 11 Mid-Day Movers 01/03: (CHNR) (FEYE) (SEED) Higher; (RFIL) (ERB) (INO) Lower
-
JMP Securities Starts Chelsea Therapeutics (CHTP) at Market Outperform
-
Pre-Open Stock Movers 11/13: (FU) (EJ) (PBPB) Higher; (YRCW) (XGTI) (CHTP) Lower (more...)
-
Chelsea Therapeutics (CHTP) Prices 6.67M Common Offering at $3/Share
-
Pre-Open Stock Movers 10/10: (ACUR) (CHTP) (NFLX) Higher; (CTXS) (RT) (CKSW) Lower (more...)
-
After-Hours Stock Movers 10/9: (ACUR) (ENZN) (CHTP) Higher; (CTXS) (RT) (CKSW) Lower (more...)
Back to CHTP Stock Lookup